The Salivary Gland NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ARID1A, ATF1, CRTC1, CRTC3, DDX3X, ETV6, EWSR1, HMGA2, MAML1, MAML2, MYB, MYBL1, MYH9, NCOA4, NFIB, NTRK1, NTRK2, NTRK3, PLAG1, PRKD1, PRKD2, PRKD3, RET, and USP6.
The Salivary Gland NGS Fusion Panel detects gene fusions that may aid in the classification of the disease and selection of patients for available therapies.
Salivary gland tumors have been reported to harbor gene fusions, such as ETV6-NTRK3, MYB-NFIB, EWSR1-ATF1, CRTC1-MAML2, and CRTC3-MAML2. Studies suggest these fusions could be therapeutic targets.
- FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
- Inaki R, Abe M, Zong L, et al. Secretory carcinoma - impact of translocation and gene fusions on salivary gland tumor. Chin J Cancer Res. 2017;29(5):379-384. doi:10.21147/j.issn.1000-9604.2017.05.01